TPH2 and breast cancer: Similar to melatonin, prolactin secretion may be driven by the central circadian pacemaker located in the SCN of the hypothalamus [42], and our observed TPH2 variant-associated increased breast-cancer risk may in addition relate to local serotonergic effects accountable for increased prolactin production in the anterior pituitary gland.